FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease
|
11 May 2023 |
FDA approves first respiratory syncytial virus (RSV) vaccine
|
04 May 2023 |
FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation
|
17 April 2023 |
FDA approves first over-the-counter naloxone nasal spray
|
29 March 2023 |
FDA grants Accelerated Approval for Alzheimer's disease treatment
|
06 January 2023 |
FDA approves new HIV drug for adults with limited treatment options
|
22 December 2022 |
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
|
16 December 2022 |
FDA approves first gene therapy to treat adults with Hemophilia B
|
22 November 2022 |
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
|
31 August 2022 |
FDA approves first systemic treatment for alopecia areata
|
13 June 2022 |
FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
|
19 May 2022 |
FDA limits use of Janssen COVID-19 vaccine to certain individuals
|
06 May 2022 |
FDA approves first generic of Symbicort to treat asthma and COPD
|
15 March 2022 |
FDA approves treatment for wider range of patients with heart failure
|
24 February 2022 |
FDA takes key action by approving second COVID-19 vaccine
|
31 January 2022 |
FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults
|
27 December 2021 |
FDA authorizes first oral antiviral for treatment of COVID-19
|
22 December 2021 |
FDA expands eligibility for Pfizer-BioNTech COVID-19 booster dose to 16- and 17-year-olds
|
09 December 2021 |
FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
|
29 October 2021 |
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
|
28 October 2021 |